A examine printed in JAMA Network Open up emphasizes the discrepancy between what it expenditures to create copyright and also the retail selling prices patients experience. Despite the very low production prices, Novo Nordisk has not publicly disclosed unique figures for copyright or its other solution, Wegovy.In October 2024, Novo Nordisk posted